Literature DB >> 10998068

Characterization of porin isoforms expressed in tumor cells.

Y Shinohara1, T Ishida, M Hino, N Yamazaki, Y Baba, H Terada.   

Abstract

Mitochondria from malignant tumor cell lines show a higher capability for hexokinase binding than those from normal liver. To explore possible differences in hexokinase binding sites of mitochondria between tumor cells and normal liver, we characterized porin isoforms expressed in tumor cells. Cloning experiments on the three porin isoforms, VDAC1, VDAC2 and VDAC3 from malignant tumor cell line AH130 clearly showed that their primary structures were completely identical to those of the corresponding VDACs of normal liver cells. Possible expression of the fourth porin isoform in AH130 cells was excluded by degenerate primer-based RT-PCR. However, the transcript levels of the three VDAC isoforms in AH130 cells were significantly higher than those in normal liver. These results suggest that the high hexokinase-binding capability of malignant tumor cell mitochondria was not due to any structural difference, but due to a quantitative difference in binding sites.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998068     DOI: 10.1046/j.1432-1327.2000.01687.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  19 in total

1.  Model of the outer membrane potential generation by the inner membrane of mitochondria.

Authors:  Victor V Lemeshko
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

Review 2.  Insights into the mitochondrial signaling pathway: what lessons for chemotherapy?

Authors:  Catherine Brenner; Morgane Le Bras; Guido Kroemer
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

3.  Pseudogenes of rat VDAC1: 16 gene segments in the rat genome show structural similarities with the cDNA encoding rat VDAC1, with 8 slightly expressed in certain tissues.

Authors:  Yusuke Ido; Takenori Yamamoto; Tatsuki Yoshitomi; Atsushi Yamamoto; Eriko Obana; Kazuto Ohkura; Yasuo Shinohara
Journal:  Mamm Genome       Date:  2011-11-20       Impact factor: 2.957

Review 4.  Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.

Authors:  S P Mathupala; Y H Ko; P L Pedersen
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

5.  Translocation of glycogen synthase kinase-3β (GSK-3β), a trigger of permeability transition, is kinase activity-dependent and mediated by interaction with voltage-dependent anion channel 2 (VDAC2).

Authors:  Masaya Tanno; Atsushi Kuno; Satoko Ishikawa; Takayuki Miki; Hidemichi Kouzu; Toshiyuki Yano; Hiromichi Murase; Toshiyuki Tobisawa; Makoto Ogasawara; Yoshiyuki Horio; Tetsuji Miura
Journal:  J Biol Chem       Date:  2014-09-03       Impact factor: 5.157

6.  Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue.

Authors:  Lewis M Brown; Steve M Helmke; Stephen W Hunsucker; Romana T Netea-Maier; Simon A Chiang; David E Heinz; Kenneth R Shroyer; Mark W Duncan; Bryan R Haugen
Journal:  Mol Carcinog       Date:  2006-08       Impact factor: 4.784

7.  Two-color STED microscopy reveals different degrees of colocalization between hexokinase-I and the three human VDAC isoforms.

Authors:  Daniel Neumann; Johanna Bückers; Lars Kastrup; Stefan W Hell; Stefan Jakobs
Journal:  PMC Biophys       Date:  2010-03-05

8.  In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death.

Authors:  Heftsi Azoulay-Zohar; Adrian Israelson; Salah Abu-Hamad; Varda Shoshan-Barmatz
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

9.  The hepatitis E virus Orf3 protein protects cells from mitochondrial depolarization and death.

Authors:  Syed Mohammad Moin; Milena Panteva; Shahid Jameel
Journal:  J Biol Chem       Date:  2007-05-08       Impact factor: 5.157

Review 10.  Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents.

Authors:  Eriko Simamura; Hiroki Shimada; Toshihisa Hatta; Kei-Ichi Hirai
Journal:  J Bioenerg Biomembr       Date:  2008-06       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.